A separate progesterone medicine can be easy to overlook when a menopause offer leads with estrogen. Alloy gives progesterone its own product page, which helps identify the proposed hormone. Yet the page does not answer every capsule question, and its one-month price display sits beside a description of a three-month supply. Those details matter before treating the offer as a complete order.
This September 29, 2026 review examines Alloy’s public product, care and transaction information. It separates the medicine’s intended role from the commercial arrangement and the label still to be checked. No supplied capsule, clinical encounter, checkout or refund was tested.
In this article
The product page establishes a pill, not a complete dispensing label
Alloy’s progesterone listing calls the treatment a prescription daily pill and labels it bioidentical and FDA-approved. It describes clinical review before prescribing and home delivery. That is stronger evidence of an actual offering than a general article about a hormone, but it is still a seller’s description rather than the label attached to a dispensed prescription.
The reviewed page does not identify a manufacturer, full inactive-ingredient list or exact capsule strength. Ask which product would be supplied and how its label can be reviewed. The capsule-excipient guide explains why a medicine name alone cannot settle an ingredient question, even when its active hormone is familiar.
The reason for the prescription should be stated separately
The Alloy page emphasizes progesterone’s role alongside estrogen for people with a uterus and says other prescribing reasons may exist. Its wording also refers to existing progestin devices. These are matters for the clinician to assess, not a checklist that lets a reader decide independently whether to add another medicine.
The FDA menopause information describes the uterine-lining concern associated with estrogen and the role of an accompanying hormone in relevant treatment. Our medicine-purpose guide helps frame a direct question: what is this particular prescription intended to accomplish within the whole plan? The answer should identify the actual hormones and routes being considered.
One-month pricing and three-month supply need reconciliation
The product header starts at $23 for a one-month supply, while the explanation of what is supplied says three months. Neither statement, alone, establishes the total that a selected order would charge. The broader HRT page separately advertises a one-time $49 doctor consultation, which should not disappear into a medication comparison.
Request the dispensing quantity, amount charged now, later billing interval and included access in one quotation. Free delivery and messaging are described, but they do not resolve the supply mismatch. Evernow’s review examines a different separation between care access and medicine costs; its membership price is not a comparable capsule price.
A familiar brand’s ingredients cannot identify Alloy’s shipment
The current Prometrium label names micronized progesterone for oral use and lists peanut oil and gelatin among its inactive ingredients. It expressly excludes use by people allergic to peanuts. Those facts concern that labeled product, rather than every medicine a menopause service might prescribe.
Without an identified Alloy preparation, this review cannot confirm either the presence or absence of those ingredients in the eventual order. A pharmacist can match the manufacturer and package information to the relevant label. A plant-derived active hormone does not, by itself, establish that the entire capsule is vegan, free of a particular allergen or suitable for someone with an ingredient concern.
Sleep language needs a practical safety conversation
Alloy’s product copy connects progesterone with sleep and also presents a broad customer symptom-relief percentage. The percentage concerns customers using menopausal hormone therapy, not a controlled comparison of this exact capsule taken alone. It cannot predict either an individual benefit or the absence of unwanted effects.
MedlinePlus identifies dizziness and drowsiness as possible effects of oral progesterone. Our drowsiness questions are a way to discuss daily activities and other medicines with the prescriber or pharmacist. This review does not turn the seller’s suggested timing into instructions or propose a different regimen when a person feels sleepy.
Renewal and product-refund rules are different promises
Alloy’s terms describe automatic subscription renewal unless canceled seven days before the period ends. Product shipments have a separate pause or cancellation deadline of five business days before processing. Service, membership and consultation charges are non-refundable; a product refund request is limited to the first shipment and must be made within thirty days of receipt.
The terms separately address damaged or missing shipments through replacement requests within fourteen days. These conditions qualify a general impression of flexibility. They do not mean stopping a commercial subscription is a clinical instruction to stop medicine. The follow-up guide keeps the next clinical discussion separate from the next payment event.
The useful comparison follows the medicine all the way to its label
The care description supports access to menopause clinicians, and the product page establishes a progesterone offer. It does not prove personal eligibility, an exact ingredient profile or superiority over another provider. A complete answer would connect the proposed role, identified preparation, pharmacy information and total purchase terms without relying on an advertising label alone.
Joi’s capsule review is a useful contrast because capsules and cream appear beside separate quarterly care charges. Their shared hormone name does not make the offers interchangeable. For Alloy, the remaining practical questions are precise: which pill, why that preparation, what supplied quantity, and who addresses a question after dispensing?
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Alloy: progesterone pill offerProvider product record; approval wording attributed, one-month price versus three-month supply unresolved; no manufacturer or supplied label confirmed · Checked 2026-09-29
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- Alloy: hormone replacement therapyProvider clinical offer and one-time consultation fee; treatment categories not a personal recommendation · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
- MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29
- Alloy: terms of useDated platform terms; subscription and shipment cancellation deadlines, first-shipment refund conditions and service-fee exclusions kept separate · Checked 2026-09-28